Forty-one percent of clinical research sites now name trial complexity their top operational problem, up from 35% a year ago, and the strain runs deeper than that single figure suggests. Two-thirds of sites describe their teams as overloaded or at risk of burnout, and fewer than a third say their current workload is sustainable, according to WCG’s fourth annual Clinical Research Site Challenges Report, drawing on responses from more than 400 clinical research professionals worldwide. The problem compounds fast: more than one in five sites now manages 150 or more active trials, the largest single group in this year’s survey.
Protocol design is where most of the damage originates. Sixty-six percent of sites rate protocol complexity a high driver of overall trial difficulty, up from 59% in 2025. Sponsor-driven design changes trigger amendments at 78% of sites, and 55% of sites spend at least a fifth of their entire start-up period just processing those amendments. That time cost alone explains why more than half of sites take three months or longer to complete study start-up, with budget development and negotiation (56%), sponsor and CRO responsiveness (43%), and CTA negotiation (38%) each named by respondents as top contributors. These are shared tasks, which means sponsors and CROs are co-owners of the delay.
NIH funding cuts have sharpened the financial exposure. Nearly two-thirds of sites say current pressures have hurt their financial performance, and sites absorbing NIH funding reductions have responded with hiring freezes or outright staff reductions. That response makes the capacity problem self-reinforcing: fewer staff, same or heavier trial loads, and no structural fix in sight. Staffing strain ranked second in the survey at 38%, contract and budget delays third at 37%, both climbing year over year.
The AI picture adds its own friction. Only 16% of sites have implemented any AI or automation, yet roughly 44% are already encountering AI-related clauses in their clinical trial agreements, meaning legal obligations are arriving well ahead of operational readiness. Sites see the greatest potential in AI-assisted participant recruitment and matching (36%) and integrated systems that end duplicate data entry (35%). If sponsors want faster starts and more sustainable sites, the report’s findings put the first intervention squarely in protocol design, before a study ever reaches a site’s door.
Source link: https://www.wcgclinical.com/2026/11/04/sites-are-paying-the-price-for-complexity-and-its-getting-steeper/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
